Induced Pluripotent Stem Cell (iPS Cells) - Content Archive

CPD-017 by Kataoka Corporation to Streamline iPSC Processing for the US Market

October 5, 2022 By Cade Hildreth, Founder & President Leave a Comment

Los Angeles, California, October 5, 2022 – Kataoka Corporation (Kyoto, Japan) and Kataoka-SS America Corporation (Carson, CA) have developed the CPD-017, a cell processing platform that uses cutting edge laser and AI technology to purify adherent iPSC cultures. [Read more…]

CellOrigin Biotech announced strategic global collaboration with Qilu Pharmaceutical to develop “off-the-shelf” CAR-iMAC cell therapy

September 19, 2022 By Cade Hildreth, Founder & President Leave a Comment

Sept. 5, 2022, China, HANGZHOU — CellOrigin Biotech (Hangzhou) Co., Ltd. announced that it has made an agreement with Qilu Pharmaceutical on strategic global collaborations to develop, manufacture and commercialize a proprietary “off-the-shelf” iPSC-derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immnotherapy. [Read more…]

Levels of Repair Inducible with Induced Pluripotent Stem Cells (iPS Cells)

September 19, 2022 By Cade Hildreth, Founder & President Leave a Comment

Induced pluripotent stem cells can be strategically utilized at several biological levels, as described below. [Read more…]

Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy

September 11, 2022 By Cade Hildreth, Founder & President Leave a Comment

August 29, 2022, MILPITAS, Calif. — Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space. [Read more…]

Laverock Therapeutics founded to develop the next generation of programmable cell therapies

September 7, 2022 By Cade Hildreth, Founder & President Leave a Comment

31^st August 2022, Stevenage, UK — Laverock Therapeutics Ltd was founded to develop a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the Company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of an experienced senior management team. [Read more…]